4 months to change everything?

#Tuberculosis  #Diabetes  #Rifapentine  #ShortCourseTreatment  #Moxifloxacin  #Safety


Tuberculosis (TB) and diabetes are two major global public health challenges, with high prevalence and significant impacts on morbidity and mortality. When they coexist in the same patient, these conditions negatively and synergistically interact, making management far more complex. Diabetes impairs the immune response, facilitating the progression of TB infection and prolonging recovery. It is also associated with a higher risk of complications, treatment relapse, and even death compared to non-diabetic patients.

In individuals with both conditions, outcomes of standard TB treatment are generally poorer. This is due to pharmacokinetic abnormalities, higher rates of comorbidities, chronic inflammation, and poor glycemic control. These factors highlight the urgent need for more tailored therapeutic strategies for this vulnerable population.

In this context, a key question arises: can a shorter yet equally effective treatment be offered to patients with both TB and diabetes?

This study investigates two shortened 4-month rifapentine-based regimens compared to the standard 6-month treatment. The goal is to assess the efficacy and safety of these approaches in individuals affected by both TB and diabetes—a population often underrepresented in clinical trials.  

Read next: MDR-TB: 9 months to change everything?

Rifapentine + Moxifloxacin: a winning combo against TB?

A total of 181 diabetic participants were enrolled and randomly assigned to one of three treatment arms:

• Standard arm (6 months): Rifampicin + Isoniazid + Pyrazinamide (first 2 months) + Ethambutol (first 2 months)
• Rifapentine/moxifloxacin arm (4 months): Rifapentine + Moxifloxacin + Isoniazid (4 months) + Pyrazinamide (first 2 months)
• Rifapentine-only arm (4 months): Rifapentine + Isoniazid (4 months) + Pyrazinamide (first 2 months) + Ethambutol (first 2 months)

The results show that the dual rifapentine/moxifloxacin combination produced the best clinical outcomes in this high-risk population. Only 13.8% of patients in this group experienced unfavorable outcomes, compared to 26.3% in the standard group and 29.4% in the rifapentine-only group. Additionally, patients in the rifapentine/moxifloxacin group achieved faster culture conversion—a key marker of treatment response. These findings suggest improved overall efficacy, including better control of active infection.

In terms of safety, the rifapentine/moxifloxacin regimen showed an equivalent or slightly better tolerance profile than the standard treatment. The rate of serious adverse events was lower (23.1% versus 31.6% in the control group), and no deaths occurred in this group during follow-up. The rates of treatment discontinuation due to side effects or poor tolerance were also lower.  

Read next: Recommendations for the management of latent tuberculosis infection.

Shorter treatment, safer future?

TB remains one of the leading causes of infectious mortality worldwide. Its management becomes even more complex when associated with diabetes—a comorbidity that is increasingly common. This dual diagnosis is linked to slower treatment response, increased relapse risk, and higher mortality.

The main challenge, therefore, is to provide effective, better-tolerated treatments adapted to this high-risk group. This study investigates the efficacy and safety of two 4-month rifapentine-based regimens in patients with both TB and diabetes.

The findings suggest that the rifapentine/moxifloxacin regimen is both effective and well-tolerated, with a lower rate of unfavorable outcomes, faster culture conversion, and fewer serious adverse events than the standard treatment. These results confirm that this shorter regimen represents an effective and safe therapeutic option, even in patients with comorbidities such as diabetes, who are traditionally considered more vulnerable to TB treatments.

Larger and more standardized studies are needed to confirm these findings. Ultimately, this strategy could shorten treatment duration, improve adherence, reduce side effects, and enhance disease control in diabetic individuals. This could lead to updated international guidelines and better integration of this population into global TB control programs.  

Read next: Mobile applications: a revolution in diabetes management?